Breaking the unvirtuous cycle: barriers and opportunities for research and development in Paraguay. A case study.

Journal: Frontiers in medicine
Published Date: Nov 16, 2023

Abstract

INTRODUCTION: Medical research and development (R&D) is an undoubtedly relevant activity to drive innovation, improve healthcare policies and bring patients treatment opportunities for common and rare diseases. Equity and inclusion are matters of concern in research. High-income countries' research teams are more likely to have more impactful publications, grant funding, and clinical trials than middle or low-income countries. Low budget allocations to R&D and existing gaps in regulatory frameworks are some obstacles to growth. This unvirtuous cycle results in scarce advances in common endemic diseases and the underrepresentation of specific populations in innovative therapeutics research.

Authors

  • María Lucila Gonzalez Donna
    Clinical Oncology Unit, Instituto Nacional del Cáncer (INCAN), Ministerio de Salud Pública y Bienestar Social (MSPyBS), Capiatá, Paraguay.
  • María Luisa Cabañas León
    Pathology Unit, Instituto Nacional del Cáncer (INCAN), Ministerio de Salud Pública y Bienestar Social (MSPyBS), Asuncion, Paraguay.
  • Cinthia Gauna Colas
    Clinical Oncology Unit, Instituto Nacional del Cáncer (INCAN), Ministerio de Salud Pública y Bienestar Social (MSPyBS), Capiatá, Paraguay.
  • Alicia Pomata Gunsett
    Pathology Unit, Instituto Nacional del Cáncer (INCAN), Ministerio de Salud Pública y Bienestar Social (MSPyBS), Asuncion, Paraguay.
  • Silvia Ferreira Maniero
    Laboratory Unit, Instituto Nacional del Cáncer (INCAN), Ministerio de Salud Pública y Bienestar Social (MSPyBS), Asuncion, Paraguay.
  • David Olivares Osuna
    Lab Manager at Cancer Heterogeneity and Hierarchies Group., Instituto Josep Carreras (IJC), Badalona, Spain.
  • Ezequiel Klimovsky
    QUID LATAM Consulting, Buenos Aires, Argentina.
  • Lucas Coradini
    Family Medicine Resident, Hospital Argerich, Buenos Aires, Argentina.
  • Diego Enrico
    Clinical Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Matías Chacón
    Clinical Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Federico Waisberg
    Clinical Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals